Home・Elenco Azioni・BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc

Chiusa

SettoreSettore sanitario

67.34 -1.51

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

66.91

Massimo

68.52

Metriche Chiave
By Trading Economics
Entrata	-61M 45M
Vendite	224M 990M
P/E Media del settore	172.2 57.002
EPS	0.9
Margine di Profitto	4.523
Dipendenti	3,221
EBITDA	50M 222M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+34.93% upside

Dividendi
By Acuity
Utili prossimi	26 ott 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	1.7B 13B
Apertura precedente	68.85
Chiusura precedente	67.34

Notizie sul Sentiment di mercato

By Acuity

98%

1 / 340 Classifica in Healthcare

BioMarin Pharmaceutical Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 ago 2026, 20:06 UTC

Biomarin Pharmaceutical Inc shares are lower today, diverging from recent gains. Broader market sentiment is mixed amid a decline in U.S. retail sales.

13 ago 2026, 22:36 UTC

Biomarin Pharmaceutical shares are higher in after-market hours, reflecting broader market positivity following the S&P 500's record close and easing inflation concerns.

12 ago 2026, 23:01 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading, with no specific news identified to explain the decline following five consecutive sessions of gains.

11 ago 2026, 19:56 UTC

Biomarin Pharmaceutical Inc shares are higher, continuing a recent upward trend. Market focus is on upcoming economic indicators, including the Consumer Price Index report.

10 ago 2026, 23:26 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading. Broader market sentiment remains cautious amid geopolitical tensions affecting investor confidence.

7 ago 2026, 23:16 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours. The broader market declined following recent labor market data affecting Federal Reserve rate hike expectations.

6 ago 2026, 23:02 UTC

News

BioMarin Pharmaceutical reported second-quarter EPS of $1.20, surpassing estimates. Shares are trading higher in after-market hours following strong revenue growth and raised guidance.

5 ago 2026, 23:56 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours amid routine trading, with no specific news identified to explain the movement.

4 ago 2026, 19:46 UTC

Biomarin Pharmaceutical Inc shares are higher, supported by broader market strength amid a decline in crude oil prices, easing inflation concerns.

3 ago 2026, 23:31 UTC

News

Biomarin Pharmaceutical shares are lower in after-market hours amid concerns over stagnant operating margins and below-average returns on capital, raising investor caution.

31 lug 2026, 20:06 UTC

Biomarin Pharmaceutical Inc shares are lower today amid broader market declines, pressured by rising Treasury yields and increased crude oil prices.

30 lug 2026, 19:08 UTC

Biomarin Pharmaceutical Inc shares are lower today, reflecting a decline since Wednesday's close amid broader economic uncertainty from rising jobless claims and weak GDP growth.

29 lug 2026, 18:14 UTC

Biomarin Pharmaceutical Inc shares are lower today, with no specific news identified. Market sentiment remains mixed amid speculation on potential Federal Reserve rate hikes.

28 lug 2026, 18:02 UTC

Biomarin Pharmaceutical is trading higher, benefiting from a strong Biotechnology sub-sector trend. Shares reached a peak earlier in the session amid favorable market conditions.

27 lug 2026, 19:01 UTC

News

BioMarin Pharmaceutical announced a collaboration with the n-Lorem Foundation to develop a treatment for ReNU syndrome, boosting shares during Monday's session.

24 lug 2026, 15:46 UTC

Biomarin Pharmaceutical shares are higher today, reflecting a broader market rebound amid a significant decline in oil prices.

22 lug 2026, 23:31 UTC

Biomarin Pharmaceutical shares traded roughly flat in after-market hours amid rising crude oil prices and geopolitical tensions affecting market sentiment.

21 lug 2026, 15:36 UTC

Biomarin Pharmaceutical Inc shares are higher as the Nasdaq gains, supported by strong technology stocks. The stock trades above its 20-day moving average.

20 lug 2026, 23:51 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, remaining above their 20-day moving average amid broader market concerns over interest rates and economic growth.

16 lug 2026, 19:06 UTC

Macro Event

News

Citi analyst raises price target on Biomarin Pharmaceutical to $76.00, maintaining a Buy rating. Shares are higher today amid positive sentiment and notable volatility.

15 lug 2026, 23:21 UTC

Biomarin Pharmaceutical shares are higher in after-market trading, nearing the upper end of their one-month range amid broader market concerns over geopolitical tensions.

14 lug 2026, 19:31 UTC

Event

Biomarin Pharmaceutical shares are lower today, tracking declines in the Biotechnology sub-sector, continuing a downward trend since Monday's close.

13 lug 2026, 19:46 UTC

News

Event

BioMarin Pharmaceutical's supplemental New Drug Application for VOXZOGO has been accepted by the FDA. Shares are lower today amid broader market sentiment.

10 lug 2026, 23:46 UTC

Biomarin Pharmaceutical shares are lower in after-market trading, retracing from earlier highs. No specific news was identified to explain the movement.

9 lug 2026, 19:16 UTC

Biomarin Pharmaceutical Inc. shares are trading roughly flat with no specific news identified. The stock remains above its 20-day moving average.

8 lug 2026, 23:46 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours, reflecting routine trading activity with minimal fluctuations and positioning above the 20-day moving average.

7 lug 2026, 23:32 UTC

Biomarin Pharmaceutical Inc. shares are higher in after-market trading, reflecting routine activity despite broader market volatility following Samsung Electronics' disappointing news.

6 lug 2026, 20:06 UTC

Biomarin Pharmaceutical shares are lower today, continuing a decline since Thursday. No specific news was identified to explain the trading activity.

2 lug 2026, 22:51 UTC

Biomarin Pharmaceutical Inc. shares were roughly flat in after-market trading, with no specific news identified. The stock has shown little change since Thursday's close.

1 lug 2026, 19:36 UTC

Biomarin Pharmaceutical Inc's shares are higher today, reaching a notable intraday high amid broader market caution and no specific company news identified.

Confronto tra pari

Modifica del prezzo

BioMarin Pharmaceutical Inc Previsione

Obiettivo di Prezzo

By TipRanks

34.93% in crescita

Previsioni per 12 mesi

Media 90.89 USD 34.93%

Alto 124 USD

Basso 60 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per BioMarin Pharmaceutical Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

19 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 19 che hanno fornito valutazioni azionarie a BioMarin Pharmaceutical Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

1 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.